Dupilumab improves histologic and endoscopic outcomes in children aged 1-11 with eosinophilic esophagitis: Results from part A of the phase 3 EOE kids study

Authors
Category Primary study
ConferencePediatric Allergy and Asthma Meeting, PAAM 2023
Year 2024
This article has no abstract
Epistemonikos ID: f7acb7bb726659bbfe77323a7cb8482f685bab07
First added on: Feb 24, 2026